Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986497 in Relapsed or Refractory AML or MDS
NCT06419634Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2024
- Primary completion
- Aug 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Molecular Glues
- Countries
- 3
01
Overview
Phase 1, open-label trial of BMS-986497 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of dose-limiting toxicities at 21 days, Incidence of treatment-emergent adverse events at 2 years and 3 more. Started May 2024; status: terminated.
02
Drugs
BMS-986497
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06419634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419634.